Pulse Biosciences (NASDAQ:PLSE) Shares Gap Up Following Insider Buying Activity

Pulse Biosciences, Inc. (NASDAQ:PLSE)’s share price gapped up before the market opened on Monday following insider buying activity. The stock had previously closed at $17.65, but opened at $18.51. Pulse Biosciences shares last traded at $19.25, with a volume of 35,220 shares.

Specifically, Director Robert W. Duggan acquired 56,054 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The shares were acquired at an average price of $17.35 per share, for a total transaction of $972,536.90. Following the completion of the purchase, the director now owns 42,228,057 shares in the company, valued at approximately $732,656,788.95. This trade represents a 0.13 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Analyst Ratings Changes

Separately, StockNews.com upgraded Pulse Biosciences to a “sell” rating in a research note on Thursday.

Pulse Biosciences Trading Up 9.7 %

The business’s fifty day simple moving average is $17.68 and its 200-day simple moving average is $16.45.

Pulse Biosciences (NASDAQ:PLSE) last issued its earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share (EPS) for the quarter. During the same quarter last year, the company earned ($0.19) EPS.

Institutional Investors Weigh In On Pulse Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. raised its holdings in Pulse Biosciences by 193.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company’s stock valued at $2,598,000 after acquiring an additional 97,565 shares during the period. Creative Planning increased its holdings in shares of Pulse Biosciences by 113.9% in the third quarter. Creative Planning now owns 21,910 shares of the company’s stock worth $384,000 after purchasing an additional 11,667 shares during the period. Cetera Advisors LLC bought a new position in shares of Pulse Biosciences in the first quarter worth $109,000. Price T Rowe Associates Inc. MD bought a new position in shares of Pulse Biosciences in the first quarter worth $88,000. Finally, Quest Partners LLC bought a new position in Pulse Biosciences in the second quarter valued at $91,000. Institutional investors own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.